Skip to main content
OABI logo

OABI · OmniAb, Inc. · Investor Relations

Track OABI — free
$5.08 +0.03 (+0.59%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$740.97M
Shares
145.86M
Volume · Nov 18 1.22M Avg daily vol (3M) 1.48M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-10-30 OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
2026-10-26 OmniAb to Participate in Upcoming Investor Conferences in November
2026-10-14 OmniAb to Report Third Quarter 2026 Financial Results on October 30
2026-10-06 OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
2026-09-14 OmniAb to Host Investor & Analyst Day on October 6, 2026
2026-08-26 OmniAb to Participate in Upcoming Investor Conferences
2026-08-17 OmniAb Raises 2026 Financial Guidance
2026-08-17 OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
2026-08-06 OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
2026-07-16 OmniAb to Report Second Quarter 2026 Financial Results on August 6
2026-07-13 OmniAb Names Amechi Nwachuku Chief Operating Officer
2026-05-07 OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
2026-04-24 OmniAb to Participate in Three Upcoming Investor Conferences
2026-04-21 OmniAb to Report First Quarter 2026 Financial Results on May 7
2026-03-04 OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2026-02-24 OmniAb to Participate at the Leerink Partners Global Healthcare Conference
2026-02-19 OmniAb to Report Fourth Quarter 2025 Financial Results on March 4
2025-12-15 Launch of OmniUltra Expands OmniAb’s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies
2025-12-04 OmniAb to Hold OmniUltra Virtual Investor Event on December 15
2025-11-17 OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
2025-11-04 OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

Past events

Date Event Type
2026-11-17 Craig-Hallum Investor Conference Conference
2026-11-12 2026 Truist Securities BioPharma Symposium Conference
2026-11-11 Stifel Healthcare Conference Conference
2026-10-30 Q3 2026 Financial Results and Business Update Call Earnings call
2026-10-06 Investor and Analyst Day Presentation
2026-09-15 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-09-09 Nasdaq/LD Micro Summit Series Event
2026-08-06 Q2 2026 Financial Results and Business Update Call Earnings call
2026-06-02 Jefferies Global Healthcare Conference Conference
2026-05-28 Benchmark 6th Annual Healthcare House Call Virtual Investor Conference Conference
2026-05-07 Q1 2026 Financial Results & Business Update call Earnings call
2026-05-06 H.C. Wainwright 2nd Annual Royalty Company Virtual Conference Conference
2026-03-10 Leerink Partners Global Healthcare Conference Conference
2026-03-04 Q4 2025 Financial Results & Business Update call Earnings call
2025-12-15 OmniUltra Launch Virtual Investor Event Event
2025-11-17 Jefferies Global Healthcare Conference – London Conference
2025-11-11 Stifel 2025 Healthcare Conference Conference
2025-11-06 2025 Truist Securities BioPharma Symposium Event
2025-11-04 Q3 2025 Financial Results & Business Update call Earnings call
2025-09-09 H.C. Wainwright 27th Annual Global Investment Conference Conference
2025-08-06 Q2 2025 Financial Results & Business Update call Earnings call
2025-06-05 Jefferies Global Healthcare Conference Conference
2025-05-29 Benchmark 2025 Healthcare House Call Virtual Conference Conference
2025-05-21 RBC Capital Markets Global Healthcare Conference Conference
2025-05-20 H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq Conference

Source: https://investors.omniab.com/overview/default.aspx

Key facts CIK 1846253 CUSIP 68218J103 13F (30d) 179 filings 167 filers Visit website Investor relations